Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Research Tools and Instruments

McGill University

$144,745.00

Robotic organoid fabrication for large throughput drug screening

EF 2023-24

Résumé
Lower respiratory infections are the fourth leading death cause worldwide presenting the highest mortality rate among communicable diseases. Presently approved treatments do not effectively combat most viral respiratory infections and the development of new antiviral drugs has been slow and difficult. This is particularly the case for viruses, such as influenza and the coronaviruses, that target the lower respiratory tract. Such viral infections are host-specific mechanisms i.e. the viruses swiftly adapt to their host environment to become genetically distinct from the viruses grown under laboratory conditions for R&D purposes. Presently, organoids are considered an excellent option for disease and treatment modeling because they can recapitulate the cellular organization and physiology of original organs by overcoming the shortcomings of other methods (animal models and 2D monocultures). This is particularly useful for studying viral-host interactions, which involve more than one cell type. Lung is the most complex organ of the human body with over 40 distinct cell types supporting complex 3D morphology. Presently, many lung organoids used to test SARS-CoV-2 viral infection only consist of a single cell type, AT2 cells, embedded in Matrigel or more mature organoids (with entire lower respiratory tract, LRT, recapitulated) display immature phenotypes and thus cannot be infected with adult viral diseases. There is a need for new lung organoids that model mature and diverse structures and cellular populations of the LRT involved in influenza H1N1 and SARS-CoV-2 infection. Our research team has developed 3D lung organoids (3DLO) that currently mimic the branching morphogenesis of the lung, and express proximal and distal markers of LRT including alveolar type I (AT1) and AT2. The application is to acquire equipment for the automation of cell culturing tasks and biofabrication of lung organoids.  We propose to buy robot control computer software, various accessories for pipette manipulation and mechanical extrusion of biomaterials, an incubator, and miscellaneous accessories.  The robotic arm is already available.  The proposed hardware would complement the actual system from a US company named "Advanced Solutions Inc.".   The principal investigator's laboratory already has a BioAssemblyBotr 400. We have used a Bio XTM bioprinter on loan from the company, which we needed to return a few months ago. The equipment is being used to print lung organoids for viral disease modeling and drug testing. With multiple viral infections emergence post-COVID pandemic, the automation of mass organoid production using the available printer can swift the process of emerging disease modeling and drug testing. For this purpose, a few accessories for the BioAssemblyBotr 400 and a new Bio XTM bioprinter are required. The requested infrastructure would create a unique lung organoid factory, essential for scaling fabrication in view of planned drug screening tests.
Programme
Research Tools and Instruments
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
RTI-2024-00607
Name nom
Mongeau, Luc
Department département
Mechanical Engineering
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2024
Award amount
144745
Program id
RTI
Program name en
Research Tools and Instruments
Program name fr
Outils et instruments de recherche
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1612
Committee name en
Mechanical Engineering (RTI)
Committee name fr
Génie mecanique (OIR)
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
2101
Research subject group en
Mechanical engineering
Research subject group fr
Solid mechanics
Research subject en
Génie mécanique
Research subject fr
Mécanique des solides
Application title
Robotic organoid fabrication for large throughput drug screening
Keyword
Biofabrication; Biomaterials; Bioprinting; COVID; Drug screening; Influenza; Lung viral infections; Organoids; Robotics
Application summary
Lower respiratory infections are the fourth leading death cause worldwide presenting the highest mortality rate among communicable diseases. Presently approved treatments do not effectively combat most viral respiratory infections and the development of new antiviral drugs has been slow and difficult. This is particularly the case for viruses, such as influenza and the coronaviruses, that target the lower respiratory tract. Such viral infections are host-specific mechanisms i.e. the viruses swiftly adapt to their host environment to become genetically distinct from the viruses grown under laboratory conditions for R&D purposes. Presently, organoids are considered an excellent option for disease and treatment modeling because they can recapitulate the cellular organization and physiology of original organs by overcoming the shortcomings of other methods (animal models and 2D monocultures). This is particularly useful for studying viral-host interactions, which involve more than one cell type. Lung is the most complex organ of the human body with over 40 distinct cell types supporting complex 3D morphology. Presently, many lung organoids used to test SARS-CoV-2 viral infection only consist of a single cell type, AT2 cells, embedded in Matrigel or more mature organoids (with entire lower respiratory tract, LRT, recapitulated) display immature phenotypes and thus cannot be infected with adult viral diseases. There is a need for new lung organoids that model mature and diverse structures and cellular populations of the LRT involved in influenza H1N1 and SARS-CoV-2 infection. Our research team has developed 3D lung organoids (3DLO) that currently mimic the branching morphogenesis of the lung, and express proximal and distal markers of LRT including alveolar type I (AT1) and AT2. The application is to acquire equipment for the automation of cell culturing tasks and biofabrication of lung organoids.  We propose to buy robot control computer software, various accessories for pipette manipulation and mechanical extrusion of biomaterials, an incubator, and miscellaneous accessories.  The robotic arm is already available.  The proposed hardware would complement the actual system from a US company named "Advanced Solutions Inc.".   The principal investigator's laboratory already has a BioAssemblyBotr 400. We have used a Bio XTM bioprinter on loan from the company, which we needed to return a few months ago. The equipment is being used to print lung organoids for viral disease modeling and drug testing. With multiple viral infections emergence post-COVID pandemic, the automation of mass organoid production using the available printer can swift the process of emerging disease modeling and drug testing. For this purpose, a few accessories for the BioAssemblyBotr 400 and a new Bio XTM bioprinter are required. The requested infrastructure would create a unique lung organoid factory, essential for scaling fabrication in view of planned drug screening tests.